%0
Generic
%T
Impact of number of lines of therapy following docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC).
%A Sonpavde, Guru
%A Bhor, Menaka
%A Hennessy, Daniel
%A Bhowmik, Debajyoti
%A Shen, Liji
%A Schnadig, Ian D.
%I American Society of Clinical Oncology (ASCO)
%@ 0732-183X
%@ 1527-7755
%K Cancer Research
%K Oncology
%D 2014
%C American Society of Clinical Oncology (ASCO)